| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We studied the tumor-surface uPA activity-dependent oncolytic recombinant Sendai virus (SeV), named BioKnife, for the treatment of ATC（anaplastic thyroid carcinoma). In vitro, uPA activity in human ATC and oral cancer cell lines was measured using a colorimetric method. Cytotoxicity of BioKnife against these cell lines was evaluated by cell count reagent. In vivo, Orthotopic models were treated with intratumoral injections of each SeV vector and were observed daily until >20% weight loss developed. All three ATC cell lines showed a high level of uPA activity. BioKnife induced dose-dependent cytotoxicity in all the cell lines. In orthotopic models, treated with BioKnife showed suppression of tumor growth and prolonged survive days.These results encourage further clinical studies for this novel agent to treat this fetal carcinoma.
|
